{
    "id": "correct_subsidiary_00122_2",
    "rank": 96,
    "data": {
        "url": "https://www.qpexbio.com/board-of-directors",
        "read_more_link": "",
        "language": "en",
        "title": "Board of Directors",
        "top_image": "https://static.wixstatic.com/media/29ee57_8bb2c055a49a4992a52f777d564ba523%7Emv2.png/v1/fit/w_2500,h_1330,al_c/29ee57_8bb2c055a49a4992a52f777d564ba523%7Emv2.png",
        "meta_img": "https://static.wixstatic.com/media/29ee57_8bb2c055a49a4992a52f777d564ba523%7Emv2.png/v1/fit/w_2500,h_1330,al_c/29ee57_8bb2c055a49a4992a52f777d564ba523%7Emv2.png",
        "images": [
            "https://static.wixstatic.com/media/29ee57_b71794fc08c842a0804ce6c5b520de07~mv2.png/v1/fill/w_359,h_118,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/id-qpex-rgb.png",
            "https://static.wixstatic.com/media/29ee57_b0ac1725d8434c53a73b7a0108145517~mv2.jpg/v1/fill/w_115,h_100,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/Qpex%252520Bio%252520Mockup%252520List%252520-%252.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://static.wixstatic.com/media/29ee57_2023c92988a3416683d4996a6b68bc9b%7Emv2.png/v1/fill/w_192%2Ch_192%2Clg_1%2Cusm_0.66_1.00_0.01/29ee57_2023c92988a3416683d4996a6b68bc9b%7Emv2.png",
        "meta_site_name": "Qpex Biopharma",
        "canonical_link": "https://www.qpexbio.com/board-of-directors",
        "text": "​​Dan Burgess\n\nExecutive Chairman of the Board\n\n​\n\nDan was President and CEO of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and subsequently sold to The Medicines Company in 2013. Prior to this, Mr. Burgess was President and CEO of Mpex Pharmaceuticals, a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Previously, he served as COO and CFO of Hollis-Eden Pharmaceuticals, a public biotechnology company focused on biodefense, infectious diseases, and immune system disorders. Mr. Burgess also spent 10 years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Ltd), where he held a variety of executive-level positions with responsibility for overall finance for the company. He began his career at Castle & Cooke and Smith Barney, Harris Upham & Co. Mr. Burgess is Chairman of Atox Bio and is a board member of Cidara Therapeutics, Arsanis, Arbutus Biopharma Corp., and Pulmocide. He received a BA in Economics from Stanford University and an MBA from Harvard Business School.\n\n​\n\nJ.C. Lopez, MD\n\nNew Enterprise Associates\n\nBoard Member\n\n​\n\nJ.C. joined NEA in 2020 as a Principal on the healthcare team focusing on life sciences investments particularly in biopharma.\n\nPrior to NEA, J.C. led Global Search and Evaluation for Neuroscience, Ophthalmology, and Rare Diseases for Roche/Genentech. While at Roche/Genentech, J.C. sourced, led, and closed Genentech's collaboration with Clover Therapeutics and was involved with Genentech's collaborations with Convelo Therapeutics and Atlanta Therapeutics. As Global Search and Evaluation Lead, he was responsible for the sourcing, triaging, and initial diligence of opportunities in neuroscience, ophthalmology, and rare diseases. Prior to Roche/Genentech, J.C. held various roles as an intern at Militia Hill Ventures, where he focused on biotech company creation and as a Tech Transfer Fellow at the University of Pennsylvania's Tech Transfer Office.\n\n​\n\nCourt Turner\n\nLYZZ Capital\n\nBoard Member\n\n​\n\nCourt Turner is a Partner at LYZZ Capital, a healthcare-focused venture capital/PE fund investing globally in leading biotech and pharmaceutical companies. Court has more than 20 years of experience in founding, operating, fundraising for and exiting life science companies. He has been a proud member of the San Diego Biotech community during his career. Before joining LYZZ Capital, he was a Venture Partner with the venture capital firm, Avalon Ventures. During his time at Avalon, Court was the Founding CEO and Director of both Synthorx, Inc. and Cellular Approaches, Inc. Prior to those roles, he was the Founding Chairman and CEO of RQx Pharmaceuticals. Prior to that, Court was a member of the executive management team at Kalypsys, Inc. Court received his JD from the University of San Diego School of Law and a BS in psychology from San Diego State University.\n\n​​​​\n\nMichael N. Dudley, PharmD\n\nPresident, CEO\n\nBoard Member\n\n​\n\nDr. Dudley has over 30 years of experience in anti-infective R&D and commercialization. In 2018, he led the Series A financing for Qpex and acquisition of the preclinical programs from The Medicines Company. He has overseen R&D and regulatory approval of multiple anti-infectives, including most recently vaborbactam that progressed from discovery to FDA approval in < 8 years. He was CSO of Rempex when it was acquired by the Medicines Company (MDCO), where he remained as co-leader of the Infectious Disease Business Unit. He has lead negotiations for multiple public-private partnerships (e.g., BARDA; Innovative Medicines Initiative) for over $190 million to advance the development of antimicrobial agents in the US and Europe. Before Rempex/MDCO, he held leadership positions of increasing responsibility at Mpex, Diversa, and Microcide. Prior to his career in industry, he held academic appointments at the University of Rhode Island College of Pharmacy and Brown University School of Medicine. He has published over 140 scientific papers/book chapters on the evaluation and clinical use of antiinfectives. He completed undergraduate work at Pepperdine University, his PharmD and residency from the University of California San Francisco (UCSF), and a fellowship in infectious diseases at Hartford Hospital.\n\n​\n\nTerry Gould\n\nAdams Street Partners\n\nBoard Member\n\n​\n\nTerry invests in venture and growth-oriented companies with a focus on the healthcare space. Terry sits on the Board of Directors of Aptinyx, Atox Bio, Corvus, Fusion Pharmaceuticals, Orbus, Outpost Medicine, Partner Therapeutics, and Qpex. He is a Board Observer at Millendo. He is a former Board Member at CombiChem, INC Research, Incline Therapeutics, and Proteus Digital Health. He is responsible for several other successful investments including Heartport, Jazz Pharmaceuticals, Naurex Pharmaceuticals, NxStage Medical, Pharmacyclics, Rempex Pharmaceuticals, Revivant, Spinal Dynamics, and Vivant Medical. Terry is Chairman of the Adams Street Partners Growth Equity Investment Committee, as well as a member of the firm's Co-Investment Committee and Executive Committee.\n\n​\n\n​\n\nDouglas Reed, MD\n\nHatteras Venture Partners\n\nBoard Member\n\n​\n\nDoug has over 20 years of venture investment experience between Hatteras and two prior healthcare-focused venture firms, Vector Fund Management and S.R. One. He has also spent part of his career in operating roles as VP of Business Development for two biotechnology companies, NPS Pharmaceuticals (acquired by Shire) and GelTex Pharmaceuticals (acquired by Genzyme). Doug focuses on investments in the bio-pharmaceutical and medical technology fields. He currently serves as Chairman of the Board of Innocrin Pharmaceuticals and is also a director of BlinkBio, Contego Medical, NeuroTronik, Ltd., and Viamet Pharmaceuticals. He was a director of Embrella Cardiovascular prior to its sale to Edwards Lifesciences. Doug earned a BA in biology and an MD from the University of Missouri – Kansas City. He completed a residency in diagnostic radiology at the University of Washington and a fellowship in neuro-radiology at the University of British Columbia. He held faculty positions in the Department of Radiology at the University of Washington and at Yale University. He also obtained an MBA in Finance from the Wharton School at the University of Pennsylvania."
    }
}